We conducted a retrospective observational study on patients with MRSA bacteremia who 6 were hospitalized between 2008 and 2011. We used univariate and multivariate analysis to 7 evaluate the predictors associated with 30-day mortality. The 7-day and 30-day mortality 8 rates were 12.0% and 25.3%, respectively. According to multivariate analysis, the 9 independent predictors that associated with 30-day mortality were leukopenia, low serum 
Introduction

Materials and methods
1
Study design and patient population 2 We conducted a retrospective observational study on patients with MRSA only the first episode of MRSA bacteremia was included in the data set.
Real-time PCR assay
24
DNA extraction and real-time PCR were performed as reported previously [12, 15] .
Bacterial DNA was extracted using Chelex (Bio-Rad Laboratories; Hercules, CA, USA), 1 methanol, and boiling methods. Real-time PCR was performed using a LightCycler 480 2 (Roche Applied Science; Mannheim, Germany) to amplify a total of 10 genes in the same run.
3
Primers and probes were purchased from Nihon Gene Research Laboratories Inc. (Miyagi, 4 Japan). The data collected between 2003 and 2007 was reported previously [12] . In this 8 study, we compared our newly obtained data (2008) (2009) (2010) (2011) with our previously obtained data 
Antimicrobial regimens and MICs
22
Initial patient antimicrobial regimens and MIC curves are shown in Fig. 1 predictors associated with 30-day mortality include hematologic malignancy, respiratory disease, hepatobiliary disease, leukopenia, low serum albumin (≤2.5 g/dL), and high SOFA 1 scores (≥5 and ≥15). Based on multivariate analysis, the independent predictors associated 2 with 30-day mortality were leukopenia (OR, 31.5; 95% CI, 3.1-322.8; P = 0.004), low serum 3 albumin (≤2.5 g/dL) (OR, 14.7; 95% CI, 1.9-116.2; P = 0.011), high SOFA score (≥15) (OR, 4 38.6; 95% CI, 3.5-431.1; P = 0.011), and use of quinolones within the previous 30 days (OR, 5 6.2; 95% CI, 1.0-38.9; P = 0.050). between the 2 studies with regard to presumed sources of infection; however, although the 15 proportion of intravascular devices used was higher in this study, the differences were not 16 significant. With regard to SOFA scores, the 2 studies did not differ significantly (6.0 ± 4.5 17 versus 5.8 ± 4.7; P = 0.739). However, the in-hospital mortality rate from this study was 18 significantly lower than in the previous study (39.8% versus 25.3%; P = 0.047).
19
A comparison of the initial antimicrobial regimens and mortality rates based on the 20 initial antimicrobial agents is shown in Table 5 . The frequency of VCM use was significantly 21 greater in this study compared to the previous study (26.5% versus 44.6%; P = 0.015). In 22 contrast, the frequency of TEIC use was significantly lower in this study (39.8% versus 23 13.3%; P < 0.001). In addition, the rate of mortality based on VCM use was significantly 24 lower in this study (59.1% versus 21.6%; P = 0.004). Whereas no changes were observed in the VCM MIC 90 between the 2 studies (Table 5) , a change was observed in the VCM trough 1 value in patients who received VCM. In this study, the VCM trough value was measured in 2 59.5% of the patients who had received VCM (22/37); the prevalence of values ≥ 10 was 3 significantly higher compared to the previous study (50.0% versus 76.0%; P = 0.031).
4
With regard to SCCmec types, the prevalence of type II was significantly lower in 5 this study compared with the previous study (79.2% versus 44.9%; P < 0.001). In contrast, 6 the prevalence of SCCmec types I and IV were higher (2.6% versus 23.1%; P < 0.001, and 7 18.2% versus 30.8%; P = 0.069) (Fig. 2) . The prevalence of tsst and sec genes was 8 significantly lower in this study (79.2% versus 52.6%; P < 0.001 and 76.6% versus 48.7%; P 9 < 0.001, respectively) (Fig. 2) . The mortality rates based on SCCmec types and virulence 10 genes could not be compared between the 2 studies because these data were not available 11 from the previous study. In this study, the 30-day mortality rates for SCCmec types I, II, and 12 IV were 11.1%, 22.9%, and 16.7%, respectively. In addition, the 30-day mortality rates based 13 on the presence or absence of virulence genes were 17.0% and 19.0%, respectively. No 14 significant differences were evident in 30-day mortality based on SCCmec types and 15 virulence genes.
Discussion
(17.0% and 19.0%, respectively). It is certain that the prevalence of virulence genes tsst and 23 sec was significantly lower in this study than in our previous study. However, the changed 24 prevalence may be related to changed SCCmec types. In this study, the prevalence of tsst and sec genes in SCCmec types I and IV was significantly lower than the prevalence of these 1 genes in SCCmec type II. Consequently, the decreased prevalence of SCCmec type II led to 2 the decreased prevalence of virulence genes.
3
In contrast, changes in patient characteristics appear to contribute to decreased 4 in-hospital mortality. Although nearly no changes were observed in patient characteristics in 5 this study, the proportion of patients who received immunosuppressive drugs or 6 corticosteroids was significantly lower than that in the previous study. The use of 7 immunosuppressive drugs or corticosteroids had served as a predictor of in-hospital mortality 8 based on univariate analysis in our previous study, and thus, the lower proportion of patients 9 on these drugs in this study may have contributed to decreased in-hospital mortality.
10
Additionally, transplantation was a predictor associated with mortality based on multivariate 11 analysis in our previous study but not in this study. Although we are unable to provide an 12 apparent explanation for why these patients decreased in this study, we have realized that 13 infection prevention in the immunocompromised host might be effective in our hospital. In within the previous 30 days was the independent predictors associated with 30-day mortality.
21
Quinolones were usually used at combination therapy in critically ill patients, but we could 22 not clarify the causation of quinolones and in-hospital mortality.
23
In conclusion, this study revealed that changes in VCM usage might contribute to 24 decreased in-hospital mortality. Recently, many studies have been conducted on the epidemiological and microbiological changes that have developed in MRSA bacteremia, but 1 few of these studies have examined how changes affect in-hospital mortality. Therefore, 2 further investigation is needed to clarify the influence that these changes have on outcomes. 
